Baird Maintains Outperform on Inari Medical, Lowers Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Baird analyst David Rescott maintains an Outperform rating on Inari Medical (NASDAQ:NARI) but lowers the price target from $65 to $63.

July 31, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst David Rescott maintains an Outperform rating on Inari Medical but lowers the price target from $65 to $63.
The Outperform rating suggests continued confidence in Inari Medical's performance, but the slight reduction in the price target indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100